Dr. A. Marc Harrison Named Upcoming CEO of Intermountain Healthcare

Published on:

SALT LAKE CITY--(BUSINESS WIRE)--The Board of Trustees of Intermountain Healthcare has selected Dr. A. Marc Harrison, 52, as the new president and CEO of Intermountain Healthcare when Dr. Charles W. Sorenson, 64, retires on October 15, 2016.

Dr. Harrison has had a distinguished career in pediatric critical care, and most recently held positions as chief of International Business Development for Cleveland Clinic, headquartered in Ohio, and CEO of the Cleveland Clinic Abu Dhabi, which is a multi-specialty hospital and part of Mubadala Healthcare’s network of world-class healthcare facilities. At Cleveland Clinic Abu Dhabi Dr. Harrison assembled a 3,500 member multi-national workforce and oversaw all aspects of clinical and business operations for the new medical campus, which cared for patients from 31 countries in its first 10 months of operations.

Earlier roles included serving as chief medical operations officer for Cleveland Clinic, where he was responsible for a broad range of clinical operations worldwide, and as chairman of Pediatric Critical Care.

“We conducted a national search and were very pleased at the high level of interest in the position from talented leaders within Intermountain and around the country,” says Intermountain Board Chair Scott Anderson, CEO of Zions Bank. “Under Dr. Sorenson’s leadership Intermountain has gained a growing local, national, and international reputation as an industry leader in providing high quality healthcare. Dr. Harrison has impressive experience and a proven track record of leading health organizations and is immensely qualified to build on Intermountain’s legacy and oversee the organization as we continue the work of transforming healthcare to meet the challenges ahead.”

Dr. Harrison earned an undergraduate degree at Haverford College and a medical degree at Dartmouth Medical School. He completed a residency and an internship in pediatric critical care through the University of Utah School of Medicine, working primarily in the critical care units of Intermountain’s Primary Children’s Hospital. His wife, Dr. Mary Carole Harrison, served as the chief resident in the same program. Dr. Marc Harrison later received a masters of Medical Management from Carnegie Mellon University and completed additional study in management at Harvard Business School.

Dr. Harrison will assume the helm when Dr. Sorenson retires as president and CEO of Intermountain Healthcare on October 15, 2016. Dr. Sorenson will continue with Intermountain as founding director of the Intermountain Healthcare Leadership Institute, which is expected to open in 2018.

 

Intermountain Healthcare is a Utah-based, not-for-profit system of 22 hospitals, 185 clinics, a Medical Group with about 1,300 employed physicians, a health plans division called SelectHealth, and other health services. Helping people live the healthiest lives possible, Intermountain is widely recognized as a leader in transforming healthcare through high quality and sustainable costs. For more information about Intermountain, visit intermountainhealthcare.org.

Related Content

FDA issues Class I recall on counterfeit infusion pump batteries
FDA issues alert on PCNL sheath safety after patient death
Bipartisan bills in Congress would force insurance companies, PBMs to sell pharmacies
Anthem BCBS reverses course on anesthesia time limits
FDA issues Class I recall on insulin syringes due to risk of death
FDA issues Class I recall on insertion tubes after manufacturing error

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.